Efficacy of a Region-Wide Lipid Management Pathway in Achieving 1-Month Low-Density Lipoprotein Target After Acute Coronary Syndrome

Q: What are the key findings of this study?

A region-wide lipid management pathway increased 1-month LDL-C <70 mg/dL achievement from 54% to 74% (P<0.001) after acute coronary syndrome.

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Acute coronary syndrome undergoing percutaneous coronary intervention (n=330). Intervention: Region-wide collaborative lipid management clinical pathway (Hiroshima Regional Collaborative Lipid Management Clinical Pathway for Ischemic Heart Disease) vs. Pre-implementation standard care. Primary outcome: Achievement of LDL-C level <70 mg/dL at 1 month after discharge (p=<0.001).

Q: What does this research mean for the field?

Implementation of a region-wide collaborative lipid management pathway significantly increases 1-month post-acute coronary syndrome LDL-C target achievement rates (<70 mg/dL and <55 mg/dL). Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To evaluate the efficacy of a region-wide collaborative lipid management clinical pathway on 1-month low-density lipoprotein cholesterol target achievement following acute coronary syndrome.

Takayuki Nakano; Hiroki Ikenaga; Toshiharu Oka; Hiroshi Sakurashita; Hiroaki Matsuo; Koutarou Miura; Mitsuo Hinoi; Kentaro Hayashi; Masashi Morita; Ryuhei Sanada; Munehiro Kanegawa; Atsushi Kuraishi; Yuki Yoshitomi; Mikio Shigehara; Haruko Shiota; Hiroshi Kobatake; Ayano Osawa; Yuichi Morita; Tasuku Higashihara; Noriaki Watanabe; Yoshiharu Sada; Kazuoki Dai; Yukiko Nakano; Kenji Nishioka

doi:10.1253/circrep.cr-26-0282

Key result

Regional lipid pathway linked to a ~20-point increase in 1-month post-ACS LDL-C target achievement.

P<0.001
n=330

Why the study?

Does a region-wide collaborative lipid management clinical pathway improve the 1-month achievement of guideline-recommended LDL-C targets (<70 mg/dL and <55 mg/dL) in patients undergoing PCI for acute coronary syndrome?

Key Points

To evaluate the efficacy of a region-wide collaborative lipid management clinical pathway on 1-month low-density lipoprotein cholesterol target achievement following acute coronary syndrome.
Conducted a multicenter before–after study across 3 institutions implementing a clinical pathway focused on early treatment intensification and structured collaboration with primary care physicians and community pharmacies.
Included 330 patients with acute coronary syndrome who had low-density lipoprotein cholesterol (LDL-C) measurements at 1-month outpatient follow-up (pre-implementation group, n=152; post-implementation group, n=178).
Attainment of LDL-C levels <70 mg/dL increased significantly from 54% in the pre-implementation group to 74% in the post-implementation group (P<0.001).
Achievement of LDL-C levels <55 mg/dL improved significantly from 25% before implementation to 39% after implementation (P=0.010).
LDL-C levels at the 1-month follow-up were significantly lower in the post-implementation group compared with the pre-implementation group (P=0.04).

Study Design

Type

Cohort (n=330)

Multicenter

Yes

Structured PICO

Does a region-wide collaborative lipid management clinical pathway improve the 1-month achievement of guideline-recommended LDL-C targets (<70 mg/dL and <55 mg/dL) in patients undergoing PCI for acute coronary syndrome?

P

Population

330 patients in Japan with acute coronary syndrome undergoing percutaneous coronary intervention (median age 71-74 years, 22.4% female) who survived to discharge and had 1-month outpatient LDL-C follow-up.

I

Intervention

Hiroshima Regional Collaborative Lipid Management Clinical Pathway for Ischemic Heart Disease: mandated in-hospital initiation of intensive statin therapy, addition of ezetimibe at discharge if LDL-C ≥70 mg/dL, structured follow-up at 1, 6, and 12 months with escalation to a PCSK9 inhibitor or familial hypercholesterolemia-equivalent statin dosing if LDL-C remained ≥70 mg/dL, mailing of the pathway to primary care physicians, and pharmacist education with an awareness sticker (<70 mg/dL target) affixed to the patient's prescription record book.

C

Comparator

Pre-implementation standard care (historical control cohort treated between July 1, 2023, and June 30, 2024, prior to clinical pathway implementation).

O

Outcome

Achievement of LDL-C levels <70 mg/dL at 1-month outpatient follow-up after hospital discharge (with achievement of LDL-C <55 mg/dL evaluated as a prespecified co-primary/key secondary outcome).surrogate

Main Result

Absolute Event Rate: 74% vs 54%

p-value: p=<0.001

Implementing a standardized, region-wide hospital-community lipid management pathway after PCI for ACS significantly improves 1-month LDL-C target attainment (<70 mg/dL and <55 mg/dL) by driving early utilization of high-intensity statins and ezetimibe.

Limitations

Retrospective nonrandomized before-after design conducted at 3 centers within a single region, leaving potential for residual confounding.
Short-term primary evaluation at 1 month after discharge, which does not assess sustained long-term efficacy or reduction in recurrent cardiovascular events.
Potential confounding from temporal changes in physician behavior, prescribing patterns, and ACS management between observational periods.
Patient selection bias due to exclusion of patients without available 1-month outpatient LDL-C measurements (only 76% pre-implementation and 75% post-implementation had available data).
Retrospective nonrandomized study conducted at 3 centers within a single region, meaning residual confounding could not be excluded despite multivariate adjustment.
Primary evaluation was based on short-term LDL-C control at 1 month after discharge rather than long-term lipid durability or recurrent cardiovascular events.
Temporal changes in physician behavior, prescribing patterns, and ACS management between the two observational periods may have contributed to the results.
Patient selection bias due to the exclusion of patients without available LDL-C measurements at the 1-month outpatient visit (24% pre-implementation and 25% post-implementation excluded).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Associated with higher LDL-C target attainment post-ACS; extends pathway evidence but leaves open randomized outcome confirmation.

Abstract

Background: Lowering low-density lipoprotein cholesterol (LDL-C) levels is the cornerstone of secondary prevention after acute coronary syndrome (ACS), but the optimal implementation strategies for achieving intensive LDL-C lowering in real-world clinical practice have not been established. Methods and Results: A multicenter before–after study was conducted across 3 institutions to evaluate the effectiveness of a region-wide collaborative lipid management clinical pathway for secondary ACS prevention. The pathway emphasized early treatment intensification and structured collaboration with primary care physicians and community pharmacy. LDL-C levels were assessed at 1-month outpatient follow-up. The primary outcomes were achievement rates of LDL-C levels <70 and <55 mg/dL. The final analysis included 330 patients with ACS (pre-implementation group, n=152; post-implementation group, n=178). The 2 groups were comparable regarding baseline clinical characteristics. At 1 month after discharge, the implementation of the clinical pathway was associated with significant improvements in the achievement of LDL-C target. The proportion of patients achieving LDL-C levels <70 mg/dL increased from 54% in the pre-implementation group to 74% in the post-implementation group (P<0.001). Achievement of LDL-C levels <55 mg/dL also improved significantly (25% vs. 39%, P=0.010). Conclusions: A region-wide collaborative lipid management pathway after ACS significantly improved early achievement of LDL-C targets via enhanced treatment intensification and coordinated post-discharge care.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nakano et al. (2026) conducted a cohort in Acute coronary syndrome undergoing percutaneous coronary intervention (n=330). Region-wide collaborative lipid management clinical pathway (Hiroshima Regional Collaborative Lipid Management Clinical Pathway for Ischemic Heart Disease) vs. Pre-implementation standard care was evaluated on Achievement of LDL-C level <70 mg/dL at 1 month after discharge (p=<0.001). A region-wide lipid management pathway increased 1-month LDL-C <70 mg/dL achievement from 54% to 74% (P<0.001) after acute coronary syndrome.

synapsesocial.com/papers/6aede416f27e0b65ad85a5e4 https://doi.org/10.1253/circrep.cr-26-0282

View Full Paper

Ask AI

Bookmark

Share

Efficacy of a Region-Wide Lipid Management Pathway in Achieving 1-Month Low-Density Lipoprotein Target After Acute Coronary Syndrome

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Efficacy of a Region-Wide Lipid Management Pathway in Achieving 1-Month Low-Density Lipoprotein Target After Acute Coronary Syndrome

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading